Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Gardasil

RFK Jr.'s vow to overhaul vaccine injury program echoes grievances of anti-vaccine movement

Health Secretary Robert F

The Independent UK

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

Benzinga

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Merck Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst consensus but overall sales experiencing a slight year-over-year decline and missing revenue expectations.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Merck: 4 No-Brainer Reasons to Buy This Dip

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

MarketBeat

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune

How RFK Jr. drove mistrust of a cancer prevention vaccine - Roll Call

President-elect Donald Trump's pick to lead HHS has a long history of discounting and peddling misinformation about the HPV vaccine.

Roll Call

Merck & Co. Stock: Is Wall Street Bullish or Bearish?

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook

Merck & Co Inc's (NYSE:MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%. Pharmaceutical sales increased 53% to $14.11 billion, primarily driven by molnupiravir, oncology, vaccines, and hospital acute care products. Pharmaceutical sales growth, excluding Lagevrio sales, was…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Children Health Defense

33 stories

Animal Health

21 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.